Federica Gatti, MD, discusses the prognostic impact of ESR1 mutations and genomic co-alterations in HR+/HER2– metastatic breast cancer.
Federica Gatti, MD
Advertisement
Federica Gatti, MD
Articles by Federica Gatti, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd
2
Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer
3
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study
4
A New Era in Pancreatic Cancer Treatment: Daraxonrasib Shakes Up the Landscape
5